米国食品医薬品局(FDA)がCOVID-19検査にPerkinElmer製品の緊急使用許可 | プレスリリース - PerkinElmer Japan

米国食品医薬品局(FDA)がCOVID-19検査にPerkinElmer製品の緊急使用許可

2020年3月24日

WALTHAM, Mass.--(BUSINESS WIRE) — 2020年3月24日--本日 ”Innovating for a healthier world”に取り組むグローバルリーダーである PerkinElmer, Inc.(NYSE:PKI)は、米国食品医薬品局(FDA)が同社の新型コロナウイルス RT-PCR 検査に緊急使用許可(EUA)を与えたと発表しました 。臨床検査室改善修正法(CLIA)で認証された臨床検査室は、COVID-19 を引き起こすウイルスである SARS-CoV-2 を検出するため、このキットを直ちに使用できます。PerkinElmer の RT-PCR 検査は、欧州の体外診断指令(IVDD)の要件を満たす事で体外診断(IVD)デバイスとして販売されており、世界 30 か国以上で利用できます。

このプレスリリースはマルチメディア向けです。フルリリースはこちらをご参照下さい:https://www.businesswire.com/news/home/20200324005766/en/


PerkinElmerの新型コロナウイルスRT-PCRテスト (写真提供: Business Wire)

パーキンエルマーの社長兼最高経営責任者である Prahlad Singh 氏は次のように述べております。「困難な環境にもかかわらず、私たちはこの 2 か月間世界的なパンデミックと戦うため、断固としたコミットメントを示しております。PerkinElmer のトータルワークフローソリューションの幅広さは、臨床診断のお客様のニーズに迅速に対応する事が出来ます。」

 

パーキンエルマー社について

PerkinElmer の提案は、科学者や研究者、臨床医にとって、科学とヘルスケア全体で最も重要な課題に取り組むことができます。”Innovating for a healthier world”というミッションの元、同社は診断、ライフサイエンス、食品およびその他分析を必要とする市場に役立つ独自のソリューションを提供しております。またお客様と戦略的に提携し、市場に対しての深い知識と技術的な専門知識により、より早く・より正確なサポートを実現致します。世界の約 13,000 人の従業員は、お客様がより健康な家庭を築き、生活の質を向上させ、世界の人々の幸福と長寿を維持するために働くことの支援に情熱を注いでいます。同社は、2019 年に約 29 億ドルの収益を報告し、190ヵ国の顧客にサービスを提供しており、S&P 500 インデックス銘柄です。追加情報は、1-877-PKI-NYSE または www.perkinelmer.com から入手できます。

 

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products exposing us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) outbreaks of communicable diseases such as COVID-19; (16) economic, political and other risks associated with foreign operations; (17) our ability to retain key personnel; (18) significant disruption in our information technology systems, or cybercrime; (19) our ability to obtain future financing; (20) restrictions in our credit agreements; (21) discontinuation or replacement of LIBOR; (22) the United Kingdom’s withdrawal from the European Union; (23) our ability to realize the full value of our intangible assets; (24) significant fluctuations in our stock price; (25) reduction or elimination of dividends on our common stock; and (26) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20200324005766/en/

Media Relations:
Brian Willinsky
(781) 663-5728
brian.willinsky@perkinelmer.com

Investor Relations:
Bryan Kipp
(781) 663-5583
bryan.kipp@perkinelmer.com

Source: PerkinElmer, Inc.